Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: February 20, 2024
Boston Scientific Corporation
By:
/s/ Daniel J. Brennan
Daniel J. Brennan
Executive Vice President and Chief Financial Officer
(duly authorized officer and principal financial officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
Dated: February 20, 2024
By:
/s/ Daniel J. Brennan
Daniel J. Brennan
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
Dated: February 20, 2024
By:
/s/ Michael F. Mahoney
Michael F. Mahoney
Director, Chairman of the Board, President and Chief Executive Officer
(Principal Executive Officer)
Dated: February 20, 2024
By:
/s/ Jonathan R. Monson
Jonathan R. Monson
Senior Vice President, Global Controller and Chief Accounting Officer
(Principal Accounting Officer)
Dated: February 20, 2024
By:
/s/ Nelda J. Connors
Nelda J. Connors
Director
Dated: February 20, 2024
By:
/s/ Charles J. Dockendorff
Charles J. Dockendorff
Director
Dated: February 20, 2024
By:
/s/ Yoshiaki Fujimori
Yoshiaki Fujimori
Director
Dated: February 20, 2024
By:
/s/ Edward J. Ludwig
Edward J. Ludwig
Director
Dated: February 20, 2024
By:
/s/ Jessica L. Mega
Jessica L. Mega
Director
Dated: February 20, 2024
By:
/s/ Susan E. Morano
Susan E. Morano
Director
Dated: February 20, 2024
By:
/s/ David J. Roux
David J. Roux
Director
Dated: February 20, 2024
By:
/s/ John E. Sununu
John E. Sununu
Director
Dated: February 20, 2024
By:
/s/ David S. Wichmann
David S. Wichmann
Director
Dated: February 20, 2024
By:
/s/ Ellen M. Zane
Ellen M. Zane
Director
Schedule II
VALUATION AND QUALIFYING ACCOUNTS
Description(in millions)
Balance at Beginning of Year
Credit loss exposure**(1)**
Write-offs**(2)**
Balance at End of Year
Year Ended December 31, 2023:
Allowances for credit losses
$
109
50
(48)
$
110
Year Ended December 31, 2022:
Allowances for credit losses
$
108
35
(35)
$
109
Year Ended December 31, 2021:
Allowances for credit losses
$
105
28
(25)
$
108
(1) We record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. Subsequent credit loss reserves are recorded when deemed uncollectible. Amounts shown within credit loss exposure above were established through selling, general and administrative expense.
(2) Represents actual write-offs of uncollectible accounts.
filings.tools